Oral Cancer Screenings
Oral cancer screenings are so important, they’re automatically a part of every visit.
Facts about Oral Cancer
Most people are surprised to learn that one American dies every hour from oral cancer; a death rate that has remained virtually unchanged for more than 40 years. In fact, recent statistics published by the American Cancer Society indicate that while the incidence and death rates for cancers overall has decreased, the incidence of oral cancer has increased by 5.5% and the death rate has increased by 1.5%.
Oral cancer is far too often discovered in late stage development, the primary reason for the consistently high death rate. Oral cancer treatment often results in disfiguring effects on patients, and can seriously compromise their quality of life. Early detection and diagnosis can make a tremendous difference in life expectancy; oral cancer is 90% curable when found in its early stages. Unfortunately, 70% of oral cancers are diagnosed in the late stages, III and IV, leading to a five-year survival rate of 57 percent.
The Deadly Statistics
- Every hour of every day, one American dies of oral cancer.
- The mortality rate associated with oral cancer has not improved significantly in the last 40 years.
- The death rate in the United States for oral cancer is higher than that of cervical and ovarian cancer, Hodgkin’s disease, cancer of the brain, liver, testes and kidneys.
- More than 30,000 Americans will receive an oral cancer diagnosis this year. In five years, only 57% will still be alive.
- 27 percent of oral cancer victims do not use tobacco or alcohol and have no other lifestyle risk factors.
VELscope Oral Screening
Recognized by the World Health Organization, Dr. van Hofwegen uses the award-winning VELscope® Vx Enhanced Oral Assessment System. This technology is a wireless, handheld scope that uses natural tissue fluorescence to detect oral mucosal abnormalities. These abnormalities, such as oral cancer or pre-malignant dysplasia are often invisible to the naked eye.
The technology is also backed by is backed by over $50 million in research and more clinical research than any other adjunctive device for tissue fluorescence visualization.